कंपनी का अवलोकन
Artiva Biotherapeutics, Inc. (ARTV) operates as a clinical-stage biotechnology entity dedicated to the development of natural killer (NK) cell-based therapies designed to treat patients suffering from autoimmune diseases and various forms of cancer. The company's primary strategic focus includes its lead product candidate, AlloNK, which represents an off-the-shelf NK cell therapy formulation specifically targeted at the autoimmune disease market segment. This enterprise functions within the broader Healthcare sector, specifically categorized under the Biotechnology industry, where innovation in cellular immunotherapy is critical for advancing patient care and therapeutic efficacy. In terms of scale, the company possesses a market capitalization of $168.07M and employs 104 individuals to execute its research and development initiatives. The valuation figure of $168.07M indicates that the market values the company's intellectual property and pipeline potential significantly higher than its current revenue generation, which is consistent with the profile of early-stage biotechnology firms that prioritize long-term clinical milestones over immediate cash flow.
वित्तीय स्वास्थ्य
The financial performance of Artiva Biotherapeutics, Inc. over the trailing twelve months reveals a net income of $-83,865,000 and an EBITDA of $-87,213,000, while the revenue figure for the same period is listed as N/A. The substantial gap between the reported net income and the EBITDA, alongside the absence of reported revenue, highlights a cost structure dominated by heavy research and development expenditures typical of clinical-stage ventures, resulting in significant operating losses. The company's free cash flow stands at $-49,240,248, a metric that underscores the capital-intensive nature of its business model and indicates that the firm is currently consuming cash reserves to fund its clinical trials and operational expansion. Regarding profitability metrics, the gross margin is recorded at 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%, which collectively signify that the company has not yet achieved commercial revenue necessary to generate positive margins or cover its direct and indirect costs. On the balance sheet, Artiva Biotherapeutics, Inc. holds $108.01M in cash against $10.94M in debt, resulting in a debt-to-equity ratio of 9.95, which suggests a highly leveraged capital structure relative to equity, yet the high cash balance provides a substantial liquidity buffer against the debt obligations. The current ratio is reported at 8.61, a figure that indicates strong short-term liquidity and the ability to cover current liabilities more than eight times over with available assets. Furthermore, the return on equity is -56.5% and the return on assets is -33.0%, metrics that reveal that management is currently utilizing shareholder and asset bases to generate negative returns due to the ongoing investment phase required to bring therapies to market.
मूल्यांकन आकलन
The valuation metrics for Artiva Biotherapeutics, Inc. show a P/E Ratio (TTM) listed as N/A due to the lack of positive net income, while the Forward P/E is reported at -2.75. The existence of a negative forward P/E implies that analysts or market models anticipate the company may not achieve profitability in the near term, reflecting the speculative nature of its valuation based on future clinical success rather than current earnings. The price-to-book ratio is 1.50, indicating that the market is valuing the company at one and a half times its book value, which suggests a moderate premium assigned to its intangible assets and clinical pipeline despite the current losses. Alternative valuation measures such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -0.81, provide additional context; the negative EV/EBITDA confirms that earnings are negative and that traditional earnings-based valuation multiples are not applicable at this stage of the company's lifecycle. Price action analysis shows a 52-week high of $7.75 and a 52-week low of $1.47, and without a specific current price provided in the facts, the company's trading range spans a wide volatility of over five times between its annual extremes, illustrating the high risk-reward profile typical of small-cap biotech stocks. The beta value is listed as N/A, meaning that the company's price volatility relative to the broader market is not quantifiable with standard metrics, likely due to low trading liquidity or data limitations common for entities with a market cap of $168.07M.
Growth & Income
Regarding growth metrics, the revenue growth year-over-year is N/A and the earnings growth year-over-year is N/A, reflecting the company's status as a pre-revenue entity where traditional growth percentages cannot be calculated. Since the company has not yet generated revenue, earnings are not growing faster or slower than revenue because neither metric exists in the traditional sense, implying that the company's primary growth driver is the progression of its clinical trials and regulatory approvals rather than top-line expansion. As a non-dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, which indicates that the company does not distribute cash to shareholders but instead retains all available resources to fund its operations and research. Consequently, Artiva Biotherapeutics, Inc. reinvests its earnings—which are currently negative but supported by its cash balance—into growth initiatives such as the development of AlloNK and other NK cell therapies rather than paying out dividends. The overall growth and income profile for Artiva Biotherapeutics, Inc. is characterized by a lack of current income generation and undefined growth rates, typical for clinical-stage biotechnology companies that rely on capital markets and cash reserves to sustain operations until commercialization milestones are achieved.